An earlier study
1 found that nonadherence with oral risperidone strongly predicted the return of psychotic symptoms in patients with a first episode of schizophrenia. Oral antipsychotic medication requires daily recommitment to treatment, which is hampered by patients’ poor awareness of the need for continued treatment. Long-acting injectable antipsychotic medication has the potential to control psychotic symptoms substantially better than short-acting medication.
2-4 However, randomized clinical trials (RCTs) of long-acting injectable antipsychotics have generally not been convincing in this regard.
5-12 Long-acting injectable antipsychotics are typically not used in the period following a first psychotic episode, instead being reserved for patients with demonstrated medication nonadherence. Ironically, when adherent, patients with a recent onset of schizophrenia usually have a more robust response to antipsychotic medications. Thus, given their frequent nonadherence with oral antipsychotics, recent-onset patients may show the clearest advantages of treatment with long-acting injectable antipsychotics.